NASDAQ · Biological Products, (No Diagnostic Substances)
Last close $11.93 · 2026-09-30
ABOUT
ExchangeNASDAQ
SectorHealthcare
IndustryBiological Products, (No Diagnostic Substances)
Market cap$1.02B
RECENT INSIDER TRADES
2026-10-06 · Bowen Matthew (Principal Accounting Officer) · SELL
2026-07-17 · Warmuth Markus (President & CEO) · SELL
2026-07-16 · Champoux Jennifer (Chief Operating Officer) · SELL
2026-07-16 · Champoux Jennifer (Chief Operating Officer) · OTHER
2026-07-07 · Townson Sharon (Chief Scientific Officer) · OTHER
INSTITUTIONAL OWNERSHIP
Institutional holders200
Shares held98,825,752
Value$2.08B
Percent of shares outstanding115.84%
As of quarter end2026-06-30
RECENT NEWS
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk - Slideshow
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
Monte Rosa plans mid-stage trials for anti-inflammatory agent after positive Phase 1 data
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk